Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche study: MabThera inhibits joint destruction

Roche study: MabThera inhibits joint destruction

23rd December 2008

Roche has announced MabThera inhibits the destruction of joints in patients who have early rheumatoid arthritis.

The phase III study examined subjects who had not been previously treated with methotrexate, the current standard of care for the treatment of the disease.

Results from the Image investigation showed that over a course of a year, there was a “significant reduction” in the rate of progressive joint damage, in comparison to the treatment of methotrexate on its own.

William Burns, chief executive of the pharmaceuticals division of Roche, said: “The results of Image show that MabThera has the potential to alter the course of rheumatoid arthritis by preventing the early damage to joints which ultimately causes deformity and disability.”

He added the “pivotal findings” add support to the case of early use of the drug for the treatment of rheumatoid arthritis, allowing sufferers to maintain a life “as normal as possible”.

Rheumatoid arthritis is an autoimmune disease, which is characterised by inflammation that leads to swollen, stiff and painful joints – resulting in irreversible joint damage and disability.

Based in Basel, Switzerland, Roche’s group sales reached 46.1 billion Swiss francs in 2007.

The company currently employs approximately 80,000 people.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.